

DAFTAR PUSTAKA

- Adjei, K., Adunlin, G., and Ali, A.A. 2023, *Impact of Sertralin, Fluoksetin, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder*. Healthcare 2023, 11, 740. <https://doi.org/10.3390/healthcare11050740>
- Agustina, T. S., Rarastanti, P. D., & Hidayat, A. F. (2021). Stress and job performance of healthcare workers amidst COVID-19 pandemic: The mediating role of burnout. *Shirkah: Journal of Economics and Business*, 6(3), 315–335. <http://dx.doi.org/10.22515/shirkah.v6i3.379>
- American Psychiatric Association. 2013, *Diagnostic and Statistical Manual of Mental Disorder (DSM-5)*, 5th edn, American Psychiatric Publishing, Washington DC.
- Amin, N. F., Garancang, S., & Abunawas, K. (2023). Konsep umum populasi dan sampel dalam penelitian. *Jurnal Pilar: Jurnal Kajian Islam Kontemporer*, 14(1), 1–12.
- Annisa, M.N., Muslim, Z., and Pudiarifanti, N. 2024, *Gambaran Penggunaan Obat Antidepresan terhadap Penderita Gangguan Depresi di RSKJ Soeprapto Kota Bengkulu*, Skripsi Diploma, Poltekkes Kemenkes Bengkulu. Tersedia di: <https://repository.poltekkesbengkulu.ac.id/3441/>
- Badan Kebijakan Pembangunan Kesehatan. 2023, *Survei Kesehatan Indonesia (SKI) 2023 dalam Angka*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Badan Penelitian dan Pengembangan Kesehatan (Balitbangkes). (2019). Laporan Nasional Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Kementerian Kesehatan RI. <https://repository.litbang.kemkes.go.id/handle/123456789/1011> (repository.litbang.kemkes.go.id in Bing)
- Baker, G. R. (2020). High performing healthcare systems: Delivering quality, value and affordability. Toronto: Longwoods Publishing.
- Berliani, A. 2022, *Studi Rasionalitas, Efek Samping dan Potensi Interaksi Antidepresan pada Pasien Depresi Rawat Jalan di Rumah Sakit Jiwa Grhasia Yogyakarta*, Skripsi S1, Fakultas Farmasi, Universitas Muhammadiyah Purwokerto. <https://repository.ump.ac.id/18277/>
- BPS_status ekonomi. 2026. <https://aryadega.com/kategori-ekonomi-di-indonesia-2024-apan-seseorang-disebut-kaya/m>
- Brunoni, A.R., Valiengo, L., Baccaro, A., Zanao, T.A., de Oliveira, J.F., Goulart, A., Boggio, P.S., Lotufo, P.A., Bensenor, I.M., and Fregni, F. 2013, *The Sertralin vs Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial, Randomized, Controlled Trial*, *JAMA Psychiatry*, 70(4):383–391. doi:10.1001/jamapsychiatry.2013.30.
- Bulloch, A. G. M., Williams, J. V. A., Lavorato, D. H., & Patten, S. B. (2017). The depression and marital status relationship is modified by both age and gender. *Journal of Affective Disorders*, 223, 65–68. <https://doi.org/10.1016/j.jad.2017.06.007>

- Cahya Legawa. (2025, Agustus 29). Montgomery-Åsberg Depression Rating Scale (MADRS): Instrumen Gold Standard untuk Evaluasi Depresi. BHYLLABUS L'ENIGME. <https://legawa.com/2025/08/29/montgomery-asberg-depression-rating-scale-madrs-instrumen-gold-standard-untuk-evaluasi-depresi/>
- Charlie Kokoh, Hafiz Addarian, Linda Anastasia, Daniel Cahyadi, 2024, *LAPORAN KASUS: GANGGUAN DEPRESI MAYOR PADA MAHASISWA FAKULTAS KEDOKTERAN*, Jurnal Pranata Biomedika, Volume 3, No 1, Maret 2024 e-ISSN: 2828-1233
- Chris F Johnson, Margaret Maxwell, Brian Williams, Nadine Dougall, Stephen MacGillivray. 2022, *Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta- narrative synthesis*, BMJMED 2022;1:e000017. doi:10.1136/bmjmed-2021-000017
- Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., dkk., (2018), *Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis*. Lancet 2018, 391, 1357–1366. [CrossRef] [https://www.thelancet.com/article/S0140-6736\(17\)32802-7/fulltext](https://www.thelancet.com/article/S0140-6736(17)32802-7/fulltext)
- Clobazam, NeuroLaunch, 26 Agustus 2024, NeuroLaunch editorial team, https://neurolaunch.com/clobazam-for-sleep/?utm_source=
- Data BPS Maluku, 2024, Badan Pusat Statistik Provinsi Maluku, <https://maluku.bps.go.id/id?utm>
- David D. Kim, PhD and Anirban Basu, PhD., 2023, *POLICY FORUM: PEER-REVIEWED ARTICLE How Does Cost-Effectiveness Analysis Inform Health Care Decisions*, AMA Journal of Ethics® August 2021, Volume 23, Number 8: E639-647
- Departemen Kesehatan Republik Indonesia, 2007, *Pharmaceutical care untuk Penderita Gangguan Depresi*, <https://farmalkes.kemkes.go.id/2013/02/pharmaceutical-care-untuk-penderita-gangguan-depresi/>
- Dipiro, J. T., Yee, G. C., Posey, L. M., Haines, S. T., Nolin, T. D., & Ellingrod, V. L., 2023, *Pharmacotherapy: A pathophysiologic approach* (13th ed.). McGraw-Hill Education.
- Edefo JW, Udezi AW. Cost Effectiveness Analysis of Sertraline Versus Amitriptyline in Depression Management in a Psychiatric Hospital in South Southern Nigeria. J Basic Sos Pharm Res. 2020;1(5):34-45
- Efseroff, B., 2025 June 16, *Major Depressive Disorder Recurrent (F33) – ICD-10 Guide for Clinicians: Guide for Mental Health Professional*, Allia Health, <https://allia.health/blog/f33-major-depressive-disorder-recurrent>
- Fahmi, M., Martini, S., & Hargono, A. (2026). Burden of depressive disorders in Indonesia: Trends and spatiotemporal analysis of DALYs lost by gender and age, 1990–2021. The Open Public Health Journal, 19(1), e18749445456022.

<https://openpublichealthjournal.com/contents/volumes/V19/e18749445456022/e18749445456022.pdf>

- Fantino, B., & Moore, N. (2009). The self-reported Montgomery-Åsberg Depression Rating Scale is a useful tool in major depressive disorder. *BMC Psychiatry*, 9(1), 26. <https://doi.org/10.1186/1471-244X-9-26>
- Fernandes, F. dos S., Pimentel, F. C., Carneiro, A. M., & Moreno, R. A. (2024). Rapid response to antidepressants and correlation with response and remission after acute treatment. *Journal of Affective Disorder Reports*. Advance online publication. <https://www.sciencedirect.com/science/article/pii/S2666915324000106>
- Fitriadi, H. (2025). Evaluation of compliance with the use of antidepressant drugs in patients depression at Dr. Radjiman Wediodiningrat Lawang Hospital, Malang Regency. Indonesia Clinical Trial Registry (INA-CTR). Retrieved from <http://etheses.uin-malang.ac.id/78571/>
- Garrison, L. P., Pauly, M. V., Willke, R. J., & Neumann, P. J. (2018). An overview of value, perspective, and decision context—A health economics approach: An ISPOR Special Task Force Report. *Value in Health*, 21(2), 124–130. <https://doi.org/10.1016/j.jval.2017.12.006>
- Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomized trials. *The Lancet*, 373(9679), 1632–1639. [https://doi.org/10.1016/S0140-6736\(09\)60742-0](https://doi.org/10.1016/S0140-6736(09)60742-0)
- Goodman, L.S., Gilman, A.G., Brunton, L.L., Hilal-Dandan, R., and Knollmann, B.C. 2023, *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 14th edn, McGraw-Hill, New York.
- Guzman, F, 2025, Fluoxetine Practical Guide: Pharmacology, Indications, dosing Guidelines and Adverse Effects. Psychopharmacology institute. Retrived from <https://psychopharmacologyinstitute.com>
- Harmer, C.J., Duman, R.S., and Cowen, P.J. 2017, *How do antidepressants work? New perspectives for refining future treatment approaches*, *The Lancet Psychiatry*, 4(5):409–418. doi:10.1016/S2215-0366(17)30015-9.
- Hawley CJ, dkk. Defining remission by MADRS: relationship to the Clinical Global Impression scale. *J Affect Disord*. 2002;72(2):117-125
- Hengartner, M. P., Angst, J., and Rössler, W. 2020, *Efficacy of new-generation antidepressants assessed with the Montgomery-Åsberg Depression Rating Scale: A meta-analysis of randomized placebo-controlled trials*. *PLOS ONE*, 15(3), e0229381. <https://doi.org/10.1371/journal.pone.0229381>
- Hidayat, S., & Puspitasari, I. M. (2021). *Adverse drug events on the use of sertraline in clinical studies: A review*. Departemen farmakologi dan farmasi Klinik Fakultas Farmasi Universitas Padjajaran. JMPF Vol 11(1), 2021. <https://doi.org/10.22146/jmpf.56558>
- Hirschfeld, R. M. A. (2001). The comorbidity of major depression and anxiety disorders: Recognition and management in primary care. *Primary care Companion to The Journal of Clinical Psychiatry*, 3(6), 244-254.

<https://pmc.ncbi.nlm.nih.gov/articles/PMC181193/#i1523-5998-003-06-0244-f01>

- Indraswari, P.I.I., Astini, N.L.S., and Yunita, E. 2022, *Profil Penggunaan Obat pada Pasien Depresi Rawat Jalan di Apotek "X" Denpasar Periode Januari–April 2022*, *Jurnal Pharmactive*, 1(2). doi:10.5281/zenodo.7265484.
- Indriasari, S. 2017, *Tingkat Depresi pada Ibu Postpartum di Puskesmas Morokrembangan Surabaya*, *Jurnal Dunia Keperawatan*, 5:43–49. Tersedia di: <https://jdk.ulm.ac.id/index.php/jdk/article/download/448/221>
- ISPOR. (2024). ISPOR pharmacoeconomic guidelines: Perspective and policy relevance in health economic evaluations. International Society for Pharmacoeconomics and Outcomes Research.
- Jeong, H. E., Jeon, H.-L., Oh, I.-S., Kim, W. J., & Shin, J.-Y. (2020). Risk of mortality associated with depression: A population-based cohort study. *BMC Medicine*, 18, 387. <https://doi.org/10.1186/s12916-020-01854-w>
- Kasper, S., dkk. 2005, Study 99024, *Unpublished Clinical Trial Data*, disintesis dalam: Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., dkk. 2018, *Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of major depressive disorder in adults: a systematic review and network meta-analysis*, *The Lancet*, 391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-7.
- Kemdi Lugard Okoroiwu, Henshaw Uchechi Okoroiwu, Love Ogochukwu Ude, Chidimma Odilia Ezuma and Emmanuel Ikechukwu Omeje, 2024, *Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023*, *Cost Effectiveness and Resource Allocation* <https://doi.org/10.1186/s12962-024-00576-7>
- Kementerian Kesehatan Republik Indonesia, 2015, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/Menkes/73/2015 tentang Pedoman Nasional Pelayanan Kedokteran Jiwa*, Jakarta: Kementerian Kesehatan RI; 2015. <https://kemkes.go.id/id/pnpk-2015---kedokteran-jiwa>
- Kementerian Kesehatan Republik Indonesia, 2024, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 16 Tahun 2024 tentang Sistem Rujukan Pelayanan Kesehatan Perseorangan*, Jakarta: Kementerian Kesehatan RI, <https://peraturan.bpk.go.id/Details/308445/permenkes-no-16-tahun-2024>
- Kementerian Kesehatan Republik Indonesia. (2020). Petunjuk teknis penilaian farmakoekonomi dalam seleksi obat. Direktorat Jenderal Kefarmasian dan Alat Kesehatan.
- Kementerian Kesehatan Republik Indonesia. (2025). Pedoman kajian farmakoekonomi dalam pelayanan kesehatan. Direktorat Produksi dan Distribusi Farmasi, Direktorat Jenderal Farmasi dan Alat Kesehatan.
- Kovacs-Zsombor Szoke, More Csaba, Kovacs-Rita Szoke, Mathe Endre, and Frecska Eda, 2020, *Selective inhibition of the serotonin transporter in the treatment of depression: Sertralin, fluoksetin and citalopram*, *Neuropsychopharmacologia Hungaria* 2020; 22(1): 4-15)
- Lee, S.Y., Wang, L.J., Yang, Y.H., and Hsu, C.W. 2022, *The comparative effectiveness of antidepressants for youths with major depressive disorder:*

- a nationwide population-based study in Taiwan, Therapeutic Advances in Chronic Disease*, 13:1–16. doi:10.1177/20406223221098114.
- Leosari Y, Uelmen JA, Carney RM. Spatial evaluation of healthcare accessibility across archipelagic communities of Maluku Province, Indonesia. *PLOS Glob Public Health*. 2023;3(3):e0001600. <https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0001600>
- Lewis, G., Duffy, L., Ades, A., Amos, R., Araya, R., Brabyn, S., Button, K. S., Churchill, R., dkk., (2019). The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): A pragmatic, double-blind, placebo-controlled randomised trial. *The Lancet Psychiatric*, 6(11), 903-914. [https://doi.org/10.1016/s2215-0366\(19\)30366-9](https://doi.org/10.1016/s2215-0366(19)30366-9)
- Lisal ST, Fattah NAMA, Indah RN, and Syamsuddin S. 2021, Comparison of Brain-derived Neurotrophic Factor Level in Depressed Patients Treated with Fluoksetin and Sertralin. *Open Access Maced J MedSci*. 2021 Jun 23; 9(T3):311-315. <https://doi.org/10.3889/oamjms.2021.6348>
- Marcel Aurelius, Wirahadi Prasadhana, Ananta Yudianto, 2022, *Meta Analysis of Correlation Between Depression and Quality of Life, Jurnal Psikogenesis Volume 10 No.1 Edisi Juni 2022, Fakultas Psikologi Universitas Surabaya, Universitas Surabaya, Surabaya, Indonesia, Email: s154221005@student.ubaya.ac.id; ananta@staff.ubaya.ac.id*
- McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & Sweden Study Group. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). *Journal of Clinical Psychiatry*, 71(2), 163–174. <https://doi.org/10.4088/JCP.08m04959>
- MedicinesFAQ. (2025, January 7). Clobazam: Uses, dosage, side effect and more. Retrieved May, 21, 2026, <https://www.medicinesfaq.com/brand/clobazam>
- Mumang AA, Liaury K, Syamsuddin S, Maria IL, Tanra AJ, Ishida T, dkk. (2020) Socio-economic-demographic determinants of depression in Indonesia: A hospital-based study. *PLoS ONE* 15(12):e0244108. <https://doi.org/10.1371/journal.pone.0244108>
- Nasir, N. M., Syamsuddin, S., Liaury, K., Tanra, A. J., Ishida, T., & Shinfuku, N. (2020). Socio-economic-demographic determinants of depression in Indonesia: A hospital-based study. *PLoS ONE*, 15(12), e0244108. <https://doi.org/10.1371/journal.pone.0244108>
- Nastaran Talaei, Shataw Azadvar, Sanaz Khodadadi, Nahal Abbasi, Zahra Najafi Asli-Pashaki, dkk., 2024, *Comparing the effect of fluoksetin, escitalopram, and sertralin, on the level of BDNF and depression in preclinical and clinical studies: a systematic review European Journal of Clinical Pharmacology* (2024) 80:983–1016 <https://doi.org/10.1007/s00228-024-03680-y>
- Neumann, P. J. (2017). *Cost-effectiveness in health and medicine* (2nd ed.). New York: Oxford University Press.

- Nita Budiyaniti, Syifa Meilinda, Robiatul Adawiyah, and Sandhy Fauzan Ramdansyah. 2023, *TINJAUAN LITERATUR PERBEDAAN ICD-10 DAN ICD-11*, Prodi D3 RMIK Cirebon, Poltekkes Kemenkes Tasikmalaya, Fakultas Kesehatan Masyarakat, Universitas Indonesia, Rumah Sakit Umum Pindad Bandung Email; robiatul.adawiyah04@ui.ac.id
- Putri, A. W., Wibhawa, B., & Gutama, A. S. (2021). Kesehatan Mental Masyarakat Indonesia (Pengetahuan, dan Keterbukaan Masyarakat Terhadap Gangguan Kesehatan Mental). *Prosiding Penelitian dan Pengabdian kepada Masyarakat*, 8(1), 1–11. DOI: 10.24198/jppm.v8i1.33234
- Putri, E.A., Susanti, S. 2025, *Implementasi Terapi Kognitif-Perilaku terhadap Komorbiditas Depresi dan Diabetes Mellitus: Sebuah Tinjauan Pustaka, Berkala Ilmiah Kedokteran dan Kesehatan Masyarakat*, 3(1). doi:10.20885/bikkm.vol3.iss1.art12.
- Ramsberg, J., Asseburg, C., and Henriksson, M. 2012, *Effectiveness and cost-effectiveness of antidepressants in primary care: A multiple treatment comparison meta-analysis and cost-effectiveness model*, *PloS ONE*, 7(8):e42003.doi:10.1371/journal.pone.0042003
<https://pubmed.ncbi.nlm.nih.gov/22876296/>
- Rapp Thomas, 2023, *Cost-effectiveness analysis*, Thomas Rapp.Cost-effectiveness Analysis.LIEPP Methods Brief n°30, 2023, 4 p. fhal-04159110, HAL Id: hal-04159110 <https://sciencespo.hal.science/hal-04159110>.
- Riedel M., Moller H.-J., Obermeier M, Response and remission criteria in major depression – A validation of current practice, <https://www.sciencedirect.com/science/article/pii/S0022395610000750>
- Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Jr., Lanzenberger, R., & Kraus, C. (2024). Relative effectiveness of antidepressant treatments in treatment-resistant depression: A systematic review and network meta-analysis of randomized controlled trials. *Neuropsychopharmacology*. <https://www.nature.com/articles/s41386-024-02044-5>
- Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., Salomon, J. A., Sculpher, M. J., & Trikalinos, T. A. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. *JAMA*, 316(10), 1093–1103. <https://doi.org/10.1001/jama.2016.12195>
- Sani A. R. Lestari, Irma M. Puspitasari, Neily Zakiyah, Elvine Gunawan, 2022, *Analisis Efektivitas Biaya Escitalopram dan Fluoksetin Dibandingkan dengan Sertralin untuk Gangguan Depresi Mayor di Salah Satu Klinik di Kota Bandung, Jurnal Farmasi Klinik Indonesia, Vol 11, No.3* <https://jurnal.unpad.ac.id/ijcp/article/view/40355>
- Santomauro, D.F., Herrera, A.M.M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D.M., dkk. 2021, *Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic, The Lancet*, 398(10312):1700–1712. doi:10.1016/S0140-6736(21)02143-7.

- Stahl, S. M., 2013, *Stahl's Essential Psychopharmacology: Neuroscientific basis and practical applications* (4th ed.), Cambridge University Press.
- Sulistiadi, W., Rahayu, S., & Harmani, N. (2021). Analisis biaya pelayanan kesehatan dari perspektif rumah sakit. Jakarta: Fakultas Kesehatan Masyarakat Universitas Indonesia.
- Suponco, S. (1993). *Pedoman Penggolongan dan Diagnosis Gangguan Jiwa (PPDGJ) III*. Jakarta: Departemen Kesehatan RI.
- Thabrany, H. (2020). Jaminan kesehatan nasional: Konsep, strategi, dan implementasi INA-CBGs di Indonesia. Jakarta: Rajawali Pers.
- Wang, P., & Si, T., 2013, Use of Antipsychotics in The Treatment of depressive Disorders, *Shanghai Archives of Psychiatry*, 25(3), 134-140, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4054548/>
- Wijkstra J, Lijmer J, Burger H, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. *Cochrane Database Syst Rev*. 2013 Nov 26;(11):CD004044. <https://doi.org/10.1002/14651858.CD004044.pub3> Updated 2021 Dec 7.
- William Hollingworth, Christopher G. Fawsitt, Padraig Dixon, Larisa Duffy, Ricardo Araya, Tim J. Peters, Howard Thom, Nicky J. Welton, Nicola Wiles, Glyn Lewis. 2020, on behalf of the PANDA Team, *Cost-Effectiveness of Sertralin in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT*, *PharmacoEconomics - Open* (2020) 4:427–438, <https://doi.org/10.1007/s41669-019-00188-5>
- World Health Organization. 2016, International Statistical classification of Diseases and Related Health Problems 10th revision (ICD-10), Version 2016, WHO Press, Geneva. <https://icd.who.int/browse10/2016/en>
- World Health Organization. 2019, World Health Statistics 2019: Monitoring Health for SDGs, WHO Press, Geneva.
- World Health Organization. 2023, International Statistical classification of Diseases and Related Health Problems 10th revision (ICD-10), Version 2023, WHO Press, Geneva. <https://icd.who.int/browse10/2023/en>
- Zhuoyue Wang, Hui Li, Yimin Kang, Yanlong liu, Ligang Shan & Fan wang (2022) *Risk of Digestive System Side-Effect of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis, Therapeutics and Clinical Risk Management*, 799-812, <https://doi.org/10.2147/TCRM.S363404>
- Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Åsberg Depression Rating Scale. *J. Clin Psychiatry*. 2004;65(2):163-168. https://www.psychiatrist.com/wp-content/uploads/2021/02/12339_defining-remission-montgomery-asberg-depression-rating.pdf